Craft

Elicio Therapeutics

Stock Price

$3.7

2024-07-05

Market Capitalization

$37.7 M

2024-07-05

Revenue

$2.3 M

FY, 2022

Elicio Therapeutics Summary

Company Summary

Overview
Elicio Therapeutics (formerly known as Vedantra Pharmaceuticals) is an immuno-oncology company developing vaccines and immunotherapies for aggressive solid and hematologic cancers. It engineers Amphiphiles that target and concentrate different immunogens in the lymph nodes, resulting in tumor or pathogen targeted immunity, including potent T cell and humoral responses.
Type
Public
Status
Active
Founded
2011
HQ
Cambridge, MA, US | view all locations
Website
https://elicio.com/
Cybersecurity rating
Sectors

Key People

  • Robert Connelly

    Robert Connelly, Chief Executive Officer & Director

  • Julian Adams

    Julian Adams, Chairman

    • Christopher Haqq

      Christopher Haqq, Executive Vice President, Head of Research and Development and Chief Medical Officer

    • Carol Ashe

      Carol Ashe, Director

      LocationsView all

      1 location detected

      • Cambridge, MA HQ

        United States

        One Kendall Square, Building 1400 West, Suite 14303

      Elicio Therapeutics Financials

      Summary Financials

      Net income (Q1, 2024)
      ($11.8M)
      Cash (Q1, 2024)
      $11.9M
      EBIT (Q1, 2024)
      ($10.2M)
      Enterprise value
      $32.5M

      Footer menu